We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Blood Test for Combined Measurements of WBCs and Biomarkers Can Predict COVID-19 Severity

By HospiMedica International staff writers
Posted on 04 Oct 2021
Image: Granulocytes are part of the innate immune system - the body’s first line of defence against pathogens (Photo courtesy of Getty Images)
Image: Granulocytes are part of the innate immune system - the body’s first line of defence against pathogens (Photo courtesy of Getty Images)

Combined measurements of characteristics of white blood cells called granulocytes and well-known biomarkers in the blood of COVID-19 patients can predict the severity of the disease, according to a new study.

The study by researchers at the Karolinska Institutet (Stockholm, Sweden) aimed at providing a comprehensive overview of the immune response to SARS-CoV-2 in hospitalized patients with moderate or severe COVID-19. The findings which showed that COVID-19 disease severity seems to be affected by granulocytes, which are part of the innate immune system, could eventually contribute to more tailored treatments for COVID-19 patients.

Granulocytes are a family of white blood cells that include neutrophils, eosinophils and basophils. They are part of the so-called innate immune system, which is the body’s first line of defence against pathogens. There are many studies on how SARS-CoV-2 affects various components of the immune system, but there is still a lack of knowledge about the role of granulocytes in COVID-19.

In the latest study, the researchers investigated the characteristics of granulocytes in the blood during the early phase of SARS-CoV-2 infection in a total of 26 hospitalized patients with COVID-19. They also performed follow-up analyses four months after hospital discharge and compared these with analyses of healthy uninfected individuals. The study found that combined measurements of granulocyte characteristics and widely used biomarkers in the blood called C-reactive protein (CRP) and creatinine, could predict key clinical features such as respiratory function and multi-organ failure.

“Our study shows significantly altered characteristics of all granulocyte subsets in COVID-19 patients and this can be linked to the severity of the disease,” said lead author Magda Lourda, who is a researcher at the Department of Medicine, Huddinge, at Karolinska Institutet. “The finding needs to be taken with caution considering the limited size of our study cohort, but our hope is that these combined measurements can be used to predict the severity of the disease, resulting in more tailored treatments for COVID-19 patients.”

Related Links:
Karolinska Institutet

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Ureteral Dilatation Balloon
Dornier Equinox

Channels

Surgical Techniques

view channel
Image: The novel approach combining MRI, fluid dynamics, and custom algorithms predicts brain cancer recurrence sites (photo courtesy of AdobeStock)

Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next

Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more